Biologics by McKesson Selected to Provide TRUSELTIQ and LUMAKRAS

BridgeBio Pharma, Inc., through its affiliate QED Therapeutics, and Helsinn Group recently announced that the FDA approved TRUSELTIQ™ (infigratinib) under the accelerated approval program for the treatment of patients with previously-treated locally advanced or metastatic cholangiocarcinoma (CCA) harboring an FGFR2 fusion or rearrangement.

TRUSELTIQ is an orally administered, ATP-competitive, tyrosine kinase inhibitor of FGFR. In the pivotal trial of patients with advanced, unresectable CCA, an aggressive malignancy with poor prognosis, TRUSELTIQ led to cases of tumor shrinkage. CCA is known to affect approximately 20,000 people in the United States and European Union each year and has a median five-year survival rate of only 9%.

Biologics by McKesson, an independent specialty pharmacy specializing in oncology and rare disease areas, has been selected by QED Therapeutics and Helsinn Group, as a specialty pharmacy provider for TRUSELTIQTM (infigratinib).

Biologics by McKesson has also been selected by Amgen Oncology as one of only eight specialty pharmacy providers for LUMAKRASTM (sotorasib) for the treatment of patients with KRAS G12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC), following at least one prior systemic therapy.

LUMAKRAS, approved by the FDA on May 28th, 2021, is a once daily orally administered KRAS G12C inhibitor. LUMAKRAS was approved through the FDA’s Priority Review pathway, which is granted to drugs that are expected to have a large impact on a disease’s treatment. This drug was also previously granted Breakthrough Therapy Designation for the treatment of patients with locally advanced or metastatic NSCLC with KRAS G12C mutation, as determined by an FDA-approved test, following at least one prior systemic therapy.

Biologics by McKesson is an independent specialty pharmacy with more than 25 years of experience connecting patients to life-changing medications in oncology and other rare and complex therapeutic areas. Biologics specialty pharmacy teams includes pharmacists with in-depth knowledge of therapies, experienced nurses, and financial counselors who are familiar with various financial assistance programs and organizations that help patients.

As part of a business within McKesson Corporation, Biologics harnesses unparalleled reach and connectivity across the healthcare system to connect the dots between payers, providers and biopharma, so together, they can deliver better care and outcomes for every patient.


Takeaway: Biologics specialty pharmacy is committed to and recognized for its level of customer service as well as its innovative, high-touch and multidisciplinary patient-centric approach